Icotrokinra results show potential to set a new standard of treatment in plaque psoriasis
Johnson & Johnson (JNJ) has announced promising Phase 3 clinical trial results for icotrokinra (JNJ-2113), a first-in-class investigational targeted oral peptide for moderate-to-severe plaque psoriasis. In the ICONIC-LEAD study, the once-daily pill demonstrated significant efficacy with 65% of patients achieving clear/almost clear skin and 50% reaching PASI 90 at Week 16, compared to 8% and 4% for placebo respectively.
By Week 24, results improved further with 74% achieving clear/almost clear skin and nearly half of patients achieving completely clear skin. The drug showed a favorable safety profile, with adverse events comparable between treatment (49%) and placebo (49%) groups.
Additionally, topline results from ICONIC-ADVANCE 1&2 studies met their primary endpoints and showed superiority to deucravacitinib. The company is now initiating the ICONIC-ASCEND study, the first head-to-head trial comparing an oral pill versus an injectable biologic (ustekinumab) in plaque psoriasis.
Johnson & Johnson (JNJ) ha annunciato risultati promettenti della fase 3 della sperimentazione clinica per icotrokinra (JNJ-2113), un peptide orale mirato di prima classe in fase di sperimentazione per la psoriasi a placche da moderata a grave. Nello studio ICONIC-LEAD, la pillola assunta una volta al giorno ha dimostrato un'efficacia significativa, con il 65% dei pazienti che ha raggiunto una pelle chiara/quasi chiara e il 50% che ha raggiunto un PASI 90 alla Settimana 16, rispetto all'8% e al 4% del gruppo placebo.
Alla Settimana 24, i risultati sono ulteriormente migliorati con il 74% che ha raggiunto una pelle chiara/quasi chiara e quasi la metà dei pazienti che ha raggiunto una pelle completamente chiara. Il farmaco ha mostrato un profilo di sicurezza favorevole, con eventi avversi comparabili tra i gruppi di trattamento (49%) e placebo (49%).
Inoltre, i risultati principali degli studi ICONIC-ADVANCE 1&2 hanno raggiunto i loro obiettivi primari e hanno mostrato superiorità rispetto al deucravacitinib. L'azienda sta ora avviando lo studio ICONIC-ASCEND, il primo trial testa a testa che confronta una pillola orale con un biologico iniettabile (ustekinumab) nella psoriasi a placche.
Johnson & Johnson (JNJ) ha anunciado resultados prometedores de ensayos clínicos de fase 3 para icotrokinra (JNJ-2113), un péptido oral dirigido de primera clase en investigación para la psoriasis en placas de moderada a grave. En el estudio ICONIC-LEAD, la píldora de una vez al día demostró una eficacia significativa, con el 65% de los pacientes logrando una piel clara/casi clara y el 50% alcanzando PASI 90 a la semana 16, en comparación con el 8% y el 4% del placebo, respectivamente.
Para la semana 24, los resultados mejoraron aún más, con el 74% logrando una piel clara/casi clara y casi la mitad de los pacientes logrando una piel completamente clara. El fármaco mostró un perfil de seguridad favorable, con eventos adversos comparables entre los grupos de tratamiento (49%) y placebo (49%).
Además, los resultados generales de los estudios ICONIC-ADVANCE 1&2 cumplieron con sus objetivos primarios y mostraron superioridad frente al deucravacitinib. La empresa ahora está iniciando el estudio ICONIC-ASCEND, el primer ensayo comparativo entre una píldora oral y un biológico inyectable (ustekinumab) en la psoriasis en placas.
존슨앤존슨 (JNJ)은 중등도에서 중증의 판상 건선 치료를 위한 최초의 조사 대상 경구 펩타이드인 이코트로킨라(JNJ-2113)의 3상 임상 시험 결과를 발표했습니다. ICONIC-LEAD 연구에서 하루 한 번 복용하는 이 약물은 65%의 환자가 깨끗한/거의 깨끗한 피부를 달성하고 50%가 PASI 90에 도달하는 등 16주 차에 유의미한 효능을 보였습니다. 이는 각각 위약군의 8%와 4%에 비해 높은 수치입니다.
24주 차에는 결과가 더욱 개선되어 74%가 깨끗한/거의 깨끗한 피부를 달성하였고, 거의 절반의 환자가 완전히 깨끗한 피부를 얻었습니다. 이 약물은 안전성 프로필이 우수하며, 치료군(49%)과 위약군(49%) 간의 부작용 발생률이 비슷했습니다.
또한, ICONIC-ADVANCE 1&2 연구의 주요 결과는 주요 목표를 달성하였고, 데우크라바시티닙에 대한 우수성을 입증했습니다. 회사는 이제 판상 건선에서 경구 약물과 주사 생물학적 제제를 비교하는 첫 번째 직접 비교 연구인 ICONIC-ASCEND 연구를 시작하고 있습니다.
Johnson & Johnson (JNJ) a annoncé des résultats prometteurs d'essais cliniques de phase 3 pour l'icotrokinra (JNJ-2113), un peptide oral ciblé de première classe en cours d'exploration pour le psoriasis en plaques modéré à sévère. Dans l'étude ICONIC-LEAD, le comprimé pris une fois par jour a démontré une efficacité significative, avec 65 % des patients atteignant une peau claire/ presque claire et 50 % atteignant un PASI 90 à la semaine 16, contre 8 % et 4 % pour le placebo respectivement.
À la semaine 24, les résultats se sont encore améliorés, avec 74 % atteignant une peau claire/ presque claire et près de la moitié des patients atteignant une peau complètement claire. Le médicament a montré un profil de sécurité favorable, avec des événements indésirables comparables entre les groupes de traitement (49 %) et de placebo (49 %).
De plus, les résultats principaux des études ICONIC-ADVANCE 1&2 ont atteint leurs objectifs principaux et ont montré une supériorité par rapport au deucravacitinib. L'entreprise lance maintenant l'étude ICONIC-ASCEND, le premier essai comparatif entre un comprimé oral et un biologique injectable (ustekinumab) dans le psoriasis en plaques.
Johnson & Johnson (JNJ) hat vielversprechende Ergebnisse der Phase-3-Studie für Icotrokinra (JNJ-2113) bekannt gegeben, ein neuartiges orales Peptid zur Behandlung von moderater bis schwerer Plaque-Psoriasis. In der ICONIC-LEAD-Studie zeigte die einmal täglich eingenommene Tablette eine signifikante Wirksamkeit, wobei 65% der Patienten eine klare/fast klare Haut erreichten und 50% PASI 90 erreichten in Woche 16, verglichen mit 8% und 4% in der Placebogruppe.
Bis Woche 24 verbesserten sich die Ergebnisse weiter, mit 74% die klare/fast klare Haut erreichten und fast die Hälfte der Patienten eine vollständig klare Haut erreichten. Das Medikament zeigte ein günstiges Sicherheitsprofil, mit vergleichbaren unerwünschten Ereignissen zwischen den Behandlungsgruppen (49%) und der Placebogruppe (49%).
Darüber hinaus erfüllten die Hauptresultate der ICONIC-ADVANCE 1&2-Studien ihre primären Endpunkte und zeigten eine Überlegenheit gegenüber Deucravacitinib. Das Unternehmen startet nun die ICONIC-ASCEND-Studie, die erste Vergleichsstudie zwischen einer oralen Tablette und einem injizierbaren Biologikum (Ustekinumab) bei Plaque-Psoriasis.
- Strong efficacy with 65% achieving clear/almost clear skin at Week 16
- Favorable safety profile comparable to placebo (49% AEs)
- Superior results to competitor drug deucravacitinib
- Novel first-in-class oral treatment option vs. injectable alternatives
- 49% of patients experienced adverse events
- 35% of patients did not achieve clear/almost clear skin by Week 16
Insights
Johnson & Johnson's clinical trial results for icotrokinra represent a significant breakthrough in plaque psoriasis treatment with multiple positive implications for the company's future growth in immunology.
The Phase 3 ICONIC-LEAD study demonstrated impressive efficacy metrics with nearly half (46%) of patients achieving completely clear skin (IGA 0) at Week 24, substantially exceeding typical outcomes for oral psoriasis medications. Additionally, the drug showed superiority to deucravacitinib in the ICONIC-ADVANCE studies, positioning it advantageously against emerging competition.
What makes icotrokinra particularly valuable is its unique mechanism as a first-in-class targeted oral peptide that selectively blocks the IL-23 receptor, combined with a favorable safety profile in a convenient once-daily pill format. This represents a potential paradigm shift from injectable biologics that currently dominate severe psoriasis treatment.
The initiation of the ICONIC-ASCEND study directly comparing icotrokinra to ustekinumab signifies J&J's confidence in the drug's potential to outperform even injectable biologics. If successful, this could establish icotrokinra as a preferred first-line systemic therapy in the moderate-to-severe plaque psoriasis market.
While regulatory approval remains pending, these robust results strongly suggest icotrokinra will become a valuable addition to J&J's immunology portfolio, potentially generating substantial future revenue in the competitive psoriasis treatment landscape.
The icotrokinra trial results represent a potential clinical advancement in psoriasis treatment that merits significant attention. The
The compound's selective IL-23 receptor blocking mechanism leverages a well-validated pathway in psoriasis pathophysiology, but delivers it through an oral formulation – addressing a major unmet need for patients who avoid injections. The comparable adverse event rates between icotrokinra (
Particularly noteworthy is icotrokinra's demonstrated superiority over deucravacitinib, another oral therapy in this space. The planned head-to-head trial against ustekinumab is unprecedented – no oral therapy has previously shown sufficient efficacy to warrant direct comparison against a leading biologic.
The inclusion of adolescents aged 12+ in the study population also represents an important advancement, as treatment options for younger patients with moderate-to-severe psoriasis remain
If approved, icotrokinra would likely become a preferred initial systemic treatment option before escalating to biologics, potentially redefining treatment algorithms while improving quality of life for psoriasis patients seeking effective oral therapy options.
Standout combination of complete skin clearance and favorable safety profile in a once daily pill could shift treatment paradigm
Nearly half of patients with moderate-to-severe plaque psoriasis (PsO) treated with investigational icotrokinra achieved completely clear skin (IGA 0) at Week 24 in Phase 3 ICONIC-LEAD
Topline results from Phase 3 ICONIC-ADVANCE 1&2 studies show icotrokinra achieved co-primary endpoints and showed superiority to deucravacitinib in moderate-to-severe plaque PsO
These results pave the way to initiate the first-ever head-to-head study seeking to demonstrate the superiority of a pill versus injectable biologic in moderate-to-severe plaque PsO
Data from the Phase 3 ICONIC-LEADa study, presented as a late-breaking abstract at the 2025 American Academy of Dermatology (AAD) Annual Meeting, show once daily icotrokinra demonstrated significant skin clearance and a favorable safety profile in adults and adolescents 12 years of age and older with moderate-to-severe plaque PsO.1
In the ICONIC-LEAD study, nearly two-thirds (
Results from a subgroup analysis of the ICONIC-LEAD study evaluating icotrokinra in the adolescent population will be presented at a forthcoming medical meeting.
"People living with moderate-to-severe plaque psoriasis are seeking options that balance efficacy, safety and ease of use," said Robert Bissonnette, M.D., Chairman at Innovaderm Research,
Additionally, topline results show that the Phase 3 ICONIC-ADVANCE 1&2e studies met their co-primary endpoints of IGA 0/1 and PASI 90 versus placebo at Week 16. Icotrokinra also met all key secondary endpoints at Weeks 16 and 24 that measured superiority to deucravacitinib in patients with moderate-to-severe plaque PsO.2,3 Based on the positive outcomes of the ADVANCE studies, Johnson & Johnson is initiating the Phase 3 ICONIC-ASCENDg study, the first-ever head-to-head study seeking to demonstrate the superiority of an oral pill, icotrokinra, compared to an injectable biologic, ustekinumab representing an important step forward in psoriasis research.
"The robust results seen to date underscore the potential for icotrokinra to shift treatment expectations in moderate-to-severe plaque psoriasis," said Liza O'Dowd, Vice President, Immunodermatology Disease Area Lead, Johnson & Johnson Innovative Medicine. "As part of our ongoing commitment to pioneer innovations for patients, we are proud to advance this first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor, which shows promise as a potential first-line systemic therapy for the treatment of plaque psoriasis."
For further details and the full list of data being presented at the 2025 AAD Annual Meeting, visit https://innovativemedicine.jnj.com/focus-areas/immunology/immudermatology-newsroom.
Editor's notes:
a. ICONIC-LEAD is a Phase 3 randomized controlled trial (RCT) evaluating the efficacy and safety of icotrokinra compared with placebo in 684 participants (icotrokinra=456; placebo=228) 12 years of age or older with moderate-to-severe plaque PsO, with the higher efficacy bar of PASI 90 and IGA score of 0/1 with at least a 2-grade improvement as co-primary endpoints. ICONIC-LEAD enrolled 66 adolescent patients.
b. The IGA is a five-point scale with a severity score ranging from 0 to 4, where 0 indicates clear, 1 is minimal, 2 is mild, 3 is moderate and 4 indicates severe disease.4
c. The PASI score grades the amount of surface area on each body region that is covered by psoriasis plaques and the severity of plaques for their redness, thickness and scaliness.5 PASI 90 corresponds to an improvement of >=
d. Dr. Robert Bissonnette is a paid consultant for Johnson & Johnson. He has not been compensated for any media work.
e. ICONIC- ADVANCE 1 & 2 are Phase 3 RCTs evaluating the efficacy and safety of icotrokinra compared with placebo and deucravacitinib in participants with moderate-to-severe plaque PsO with PASI 90 and IGA score of 0/1 with at least a 2-grade improvement as co-primary endpoints.
f. ICONIC-ASCEND is a Phase 3 RCT and the first-ever head-to-head study seeking to demonstrate the superiority of an oral pill, icotrokinra, compared to an injectable biologic, ustekinumab in moderate-to-severe plaque PsO.
About the ICONIC Clinical Development Program
The pivotal Phase 3 ICONIC clinical development program of icotrokinra (JNJ-2113) in adult and adolescent individuals with moderate-to-severe plaque PsO was initiated with two studies in Q4 2023 – ICONIC-LEAD and ICONIC-TOTAL – pursuant to the license and collaboration agreement between Protagonist Therapeutics, Inc. and Janssen Biotech, Inc., a Johnson & Johson company.6
ICONIC-LEAD (NCT06095115) is a randomized controlled trial (RCT) to evaluate the efficacy and safety of icotrokinra compared with placebo in participants with moderate-to-severe plaque PsO, with PASI 90 and IGA score of 0 or 1 with at least a 2-grade improvement as co-primary endpoints.7
ICONIC-TOTAL (NCT06095102) is a RCT to evaluate the efficacy and safety of icotrokinra compared with placebo for the treatment of PsO in participants with at least moderate severity affecting special areas (e.g., scalp, genital, and/or hands and feet) with overall IGA score of 0 or 1 with at least a 2-grade improvement as the primary endpoint.8
Other Phase 3 studies in the development program include ICONIC-ADVANCE 1 (NCT06143878) and ICONIC-ADVANCE 2 (NCT06220604), which are evaluating the efficacy and safety of icotrokinra compared with both placebo and deucravacitinib in adults with moderate-to-severe plaque PsO.9,10 ICONIC-ASCEND will evaluate the efficacy and safety of icotrokinra compared with placebo and ustekinumab in participants with moderate-to-severe plaque psoriasis. ICONIC-PsA 2 (NCT06807424) will evaluate the efficacy and safety of icotrokinra compared to placebo in participants with active psoriatic arthritis.
About Plaque Psoriasis
Plaque psoriasis (PsO) is a chronic immune-mediated disease resulting in overproduction of skin cells, which causes inflamed, scaly plaques that may be itchy or painful.11 It is estimated that 8 million Americans and more than 125 million people worldwide live with the disease.12 Nearly one-quarter of all people with plaque PsO have cases that are considered moderate to severe.11 On Caucasian skin, plaques typically appear as raised, red patches covered with a silvery white buildup of dead skin cells or scale.13 On skin of color, the plaques may appear darker and thicker and more of a purple, gray or dark brown color.12 Plaques can appear anywhere on the body, although they most often appear on the scalp, knees, elbows and torso.12 Living with plaque PsO can be a challenge and impact life beyond a person's physical health, including emotional health, relationships, and handling the stressors of life.14 Psoriasis on highly visible areas of the body or sensitive skin, such as the scalp, hands, feet, and genitals, can have an increased negative impact on quality of life.12,15
About Icotrokinra (JNJ-77242113, JNJ-2113)
Investigational icotrokinra is the first targeted oral peptide designed to selectively block the IL-23 receptor,16 which underpins the inflammatory response in moderate-to-severe plaque psoriasis (PsO), ulcerative colitis (UC) and offers potential in other IL-23-mediated diseases.17,18 Icotrokinra binds to the IL-23 receptor with single-digit picomolar affinity and demonstrated potent, selective inhibition of IL-23 signaling in human T cells.19 The license and collaboration agreement established between Protagonist Therapeutics, Inc. and Janssen Biotech, Inc., a Johnson & Johnson company, in 2017 enabled the companies to work together to discover and develop next-generation compounds that ultimately led to icotrokinra.20
Icotrokinra was jointly discovered and is being developed pursuant to the license and collaboration agreement between Protagonist and Johnson & Johnson. Johnson & Johnson retains exclusive worldwide rights to develop icotrokinra in Phase 2 clinical trials and beyond, and to commercialize compounds derived from the research conducted pursuant to the agreement against a broad range of indications.21,22,23
Icotrokinra is being studied in the pivotal Phase 3 ICONIC clinical development program in moderate-to-severe plaque PsO and active psoriatic arthritis and the Phase 2b ANTHEM-UC study in moderately to severely active UC.
About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.
Learn more at https://www.jnj.com/ or at www.innovativemedicine.jnj.com.
Follow us at @JNJInnovMed.
Janssen Research & Development, LLC and Janssen Biotech, Inc. are Johnson & Johnson companies.
Cautions Concerning Forward-Looking Statements
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding icotrokinra (JNJ-2113). The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Research & Development, LLC, Janssen Biotech, Inc. and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of Janssen Research & Development, LLC, Janssen Biotech, Inc. nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.
1 Bissonnette, R et al. Icotrokinra, a Targeted Oral Peptide That Selectively Blocks the Interleukin-23–Receptor, for the Treatment of Moderate-to-Severe Plaque Psoriasis: Results Through Week 24 of the Phase 3, Randomized, Double-blind, Placebo-Controlled ICONIC-LEAD Trial. Late-breaking research presentation (Abstract #66708) at the American Academy of Dermatology (AAD) 2024 Annual Meeting. March 2025.
2 Data on file.
3 Data on file.
4 Simpson E, Bissonnette R, Eichenfield LF, et al. The validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis [published online April 25, 2020]. J Am Acad Dermatol. doi: 10.1016/j.jaad.2020.04.104. Accessed March 2025.
5 Thompson Jr, D. How the Psoriasis Area and Severity Index works. Everyday Health. Available at: https://www.everydayhealth.com/psoriasis/living-with/how-the-pasi-index-works. Accessed March 2025.
6 Protagonist Therapeutics. Press release. Protagonist announces advancement of JNJ-2113 across multiple indications. Available at: https://www.accesswire.com/791174/protagonist-announces-advancement-of-jnj-2113-across-multiple-indications. Accessed March 2025.
7 Clinicaltrials.gov. A study of JNJ-2113 in adolescent and adult participants with moderate-to-severe plaque psoriasis (ICONIC-LEAD). Identifier NCT06095115. https://classic.clinicaltrials.gov/ct2/show/NCT06095115. Accessed March 2025.
8 Clinicaltrials.gov. A study of JNJ-2113 for the treatment of participants with plaque psoriasis involving special areas (scalp, genital, and/or palms of the hands and the soles of the feet) (ICONIC-TOTAL). Identifier NCT06095102. https://classic.clinicaltrials.gov/ct2/show/NCT06095102. Accessed March 2025.
9 Clinicaltrials.gov. A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis. Identifier NCT06143878. https://clinicaltrials.gov/study/NCT06143878?term=jnj-77242113&rank=10. Accessed March 2025.
10 Clinicaltrials.gov. A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2). Identifier NCT06220604. https://clinicaltrials.gov/study/NCT06220604. Accessed March 2025.
11 National Psoriasis Foundation. About Psoriasis. Available at: https://www.psoriasis.org/about-psoriasis. Accessed March 2025.
12 National Psoriasis Foundation. Psoriasis Statistics. Available at: https://www.psoriasis.org/content/statistics. Accessed March 2025.
13 National Psoriasis Foundation. Plaque Psoriasis. Available at: https://www.psoriasis.org/plaque/. Accessed March 2025.
14 National Psoriasis Foundation. Life with Psoriasis. Available at: https://www.psoriasis.org/life-with-psoriasis/. Accessed March 2025.
15 National Psoriasis Foundation. High Impact Sites. Available at: https://www.psoriasis.org/high-impact-sites/. Accessed Sep March 2025.
16 Bissonnette R, et al. Data presentation. A phase 2, randomized, placebo-controlled, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis: FRONTIER 1. Presented at WCD 2023, July 3-8.
17 Razawy W, et al. The role of IL‐23 receptor signaling in inflammation‐mediated erosive autoimmune arthritis and bone remodeling. Eur J Immunol. 2018 Feb; 48(2): 220–229.
18 Tang C, et al. Interleukin-23: as a drug target for autoimmune inflammatory diseases. Immunology. 2012 Feb; 135(2): 112–124.
19 Pinter A, et al. Data Presentation. JNJ-77242113 Treatment Induces a Strong Systemic Pharmacodynamic Response Versus Placebo in Serum Samples of Patients with Plaque Psoriasis: Results from the Phase 2, FRONTIER 1 Study. Presented at EADV 2023, October 11-14.
20 Johnson & Johnson. Press release. Janssen enters into worldwide exclusive license and collaboration agreement with Protagonist Therapeutics, Inc. for the oral Interlukin-23 receptor antagonist drug candidate for the treatment of Inflammatory Bowel Disease. Available at: https://www.jnj.com/media-center/press-releases/janssen-enters-into-worldwide-exclusive-license-and-collaboration-agreement-with-protagonist-therapeutics-inc-for-the-oral-interlukin-23-receptor-antagonist-drug-candidate-for-the-treatment-of-inflammatory-bowel-disease. Accessed March 2025.
21 Protagonist Therapeutics. Press release. Protagonist Therapeutics announces amendment of agreement with Janssen Biotech for the continued development and commercialization of IL-23 antagonists. Available at: https://www.prnewswire.com/news-releases/protagonist-therapeutics-announces-amendment-of-agreement-with-janssen-biotech-for-the-continued-development-and-commercialization-of-il-23-antagonists-301343621.html. Accessed March 2025.
22 Protagonist Therapeutics. Press release. Protagonist Reports positive results from Phase 1 and pre-clinical studies of oral Interleukin-23 receptor antagonist JNJ-2113. Available at: https://www.prnewswire.com/news-releases/protagonist-reports-positive-results-from-phase-1-and-pre-clinical-studies-of-oral-interleukin-23-receptor-antagonist-jnj-2113-301823039.html. Accessed March 2025.
23 Protagonist Therapeutics. Press release. Protagonist Therapeutics announces positive topline results for Phase 2b FRONTIER 1 clinical trial of oral IL-23 receptor antagonist JNJ-2113 (PN-235) in psoriasis. Available at: https://www.prnewswire.com/news-releases/protagonist-therapeutics-announces-positive-topline-results-for-phase-2b-frontier-1-clinical-trial-of-oral-il-23-receptor-antagonist-jnj-2113-pn-235-in-psoriasis-301764181.html. Accessed March 2025.
Media contact:
| Investor contact: |
View original content to download multimedia:https://www.prnewswire.com/news-releases/icotrokinra-results-show-potential-to-set-a-new-standard-of-treatment-in-plaque-psoriasis-302396171.html
SOURCE Johnson & Johnson
FAQ
What are the key efficacy results of icotrokinra (JNJ-2113) in the Phase 3 ICONIC-LEAD trial?
How does the safety profile of JNJ's icotrokinra compare to placebo in psoriasis treatment?
What makes JNJ's icotrokinra unique in psoriasis treatment?
What is the significance of JNJ's ICONIC-ASCEND study for psoriasis treatment?
